CRISPR Therapeutics - Business Information
Manufacturing · Switzerland · 473 Employees
Crispr Therapeutics, founded in 2013 and headquartered in Zug, Switzerland, is a developer of gene-based medications that target diseases at the molecular level.
View Company Info for Free
Who is CRISPR Therapeutics
CRISPR Therapeutics Org Chart
CRISPR Therapeutics Company Metrics
Total Funding Amount
Most Recent Funding Amount
Number of Funding Rounds
CRISPR Therapeutics News & Media
- CRISPR Therapeutics AG (NASDAQ:NASDAQ:CRSP) Citi's 18th Annual BioPharma Conference Call September 6, 2023 11:20 AM ETCompany ParticipantsSam Kulkarni - CEO Conference Call...
- Key Insights Institutions' substantial holdings in CRISPR Therapeutics implies that they have significant influence...
- ZUG, Switzerland and CAMBRIDGE, Mass., June 13, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in a fireside chat at the 44th Annual Goldman Sachs Global Healthcare Conference being held from June 12th- 15th, 2023.
Positive Results From Pivotal Trials of exa-cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease Presented at the 2023 Annual European Hematology Association (EHA) CongressBOSTON & ZUG, Switzerland--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced that both pivotal trials for exagamglogene autotemcel (exa-cel) in patients with transfusion-dependent beta thalassemia (TDT) or severe sickle cell disease (SCD) met primary and key secondary endpoints at pre-specified interim analyses. The results are being presented at the Annual European Hematology Association (EHA) Congress. “The updated resul
Frequently Asked Questions regarding CRISPR Therapeutics
Crispr Therapeutics, founded in 2013 and headquartered in Zug, Switzerland, is a developer of gene-based medications that target diseases at the molecular level....